(Information sent by the signatory company)
MEDSIR, based in Barcelona and New Jersey, will once again have a prominent presence at the largest world congress of medical oncology, presenting together with its partner Oncoclínicas & Co, a total of thirteen studies, including an oral presentation. Presence at the congress represents a scientific milestone for the company and recognition of independent clinical research focused on patients with limited therapeutic options.
Chicago, June 3, 2024.- MEDSIR, a leading company dedicated to promoting independent clinical research in oncology internationally, has returned this year to the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, the world’s leading cancer congress, to present new options aimed at patients with breast cancer with few therapeutic alternatives. Among the most relevant studies, PRIMED stands out, whose strategy seeks effectiveness in reducing side effects caused by medication in patients with HER2-negative metastatic breast cancer. The study determines whether the combination of granulocyte-stimulating factors with loperamide during the first 2 cycles of treatment with sacituzumab govitecan can improve tolerance or increase the efficacy of the therapy, evaluating toxicity, safety and adverse effects. Its strategy seeks to reduce two of the most common side effects of sacituzumab govitecan: diarrhea and neutropenia.
Presence at the congress represents a scientific milestone for the company and recognition of the independent clinical research promoted by Spanish oncologists. After publication in the prestigious scientific journal The Lancet Based on the results of the PHERGain clinical trial, which demonstrate that one third of patients with localized HER2-positive breast cancer can be treated without the need for chemotherapy, MEDSIR is now also focusing on other unmet needs of patients with advanced breast cancer to those for which there are no therapeutic options with curative intent. “Our objective in patients with advanced breast cancer is to prolong their survival and improve their quality of life, so it is essential to look for strategies that improve the tolerance of current oncological treatments,” says the Dr. José Pérez, associate physician of MEDSIR and deputy director of the International Breast Cancer Center – IBCC. MEDSIR, together with its strategic partner Oncoclínicas & Co, the largest private hospital network in Latin America, has presented a total of 13 studies during the congress.
Innovative trials to reach more patients
Beyond the PRIMED clinical trial, other trials also stand out such as TUXEDO-3, carried out in Spanish and Austrian hospitals with the participation of Dr. Matthias Preusser, director of the clinical division of oncology at the Medical University of Vienna (Austria). TUXEDO-3 is a phase II clinical trial and is the first study to evaluate the efficacy and safety over time of patritumab deruxtecan in patients with pretreated metastatic breast cancer and advanced non-small cell lung cancer with brain metastases. , as well as patients with other metastatic solid tumors and leptomeningeal disease. If the results of this study are positive, the use of patritumab deruxtecan could be implemented in these groups of patients, whose therapeutic options are currently very limited.
Likewise, an exploratory substudy of the trial also highlights PHERGain on localized HER2-positive breast cancer. In it, the results of the PET scan are compared with magnetic resonance imaging, examinations that PHERGain patients undergo to observe the evolution of the response to treatment. This comparative study evaluates whether instead of PET, which is the recommended imaging technique to evaluate the early response to treatment, magnetic resonance could be used as an alternative to guide therapy following the PHERGain strategy in those cases in which there is no availability of the PET scanner (since currently not all hospitals have access to this imaging modality).
Lastly, the study PATHFINDER explores possible new therapeutic options for patients with advanced aggressive breast cancer or with metastasis, who have a median survival of less than 2 years. The study evaluates which combination of two drugs – a novel therapy together with different conventional chemotherapies – is most effective for this group of patients.
“Thanks to the quality of the preparation of this type of studies, we can reach hopeful results that improve the quality of life of patients with innovative treatments,” says the Dr. José Pérez. This is the great purpose of the company, to promote research to bring new treatments to the patient thanks to the advances generated by research in clinical practice.
The incidence of metastatic breast cancer
According to the Metastatic Breast Cancer Association, 30% of the 33,000 new cases of breast tumors detected each year will end in metastasis.[1]. Around 80% of women who are diagnosed with a breast tumor overcome the disease, but in the remaining 20% the treatments are not effective. This percentage has been reducing in recent decades thanks to therapeutic advances arising from a better knowledge of cancer biology.
On the other hand, the American Cancer Society, points out the existence of the concept of ‘advanced cancer’, used to refer to a stage of cancer in which the disease has progressed to a point where it is more difficult to treat and less likely to be cured. However, in some cases, this type of cancer can be kept under control for a very long period, becoming considered a continuous or chronic disease. Even if the cancer cannot be cured, treatment can sometimes help reduce its size, slow its growth, help relieve symptoms, or live longer.[2].
About MEDSIR
Established in 2012, MEDSIR is distinguished by its close collaboration with strategic partners to drive innovation in oncology research. Based in Spain and the United States, the company is responsible for the comprehensive management of clinical trials, ranging from study design to its subsequent publication, relying on an extensive global network of experts and integrated technology to streamline the process. The company offers proof-of-concept support and a strategic approach that enables research partners to benefit from the best of both worlds: industry clinical research and investigator-driven trials.
With the aim of promoting independent research globally, MEDSIR has established a strategic alliance with Oncoclínicas, the leading oncology group in Brazil with outstanding research potential in South America.
For more information: www.medsir.org
[1] Metastatic Breast Cancer Association. A silenced pandemic. April 2022. Link
[2] American Cancer Society. Understanding advanced and metastatic cancer. September 2020. Link
Contact
Contact name: Sergio Aguilar
Contact Description: Global Brand & Communication Director
Contact telephone number: +34 674 82 87 24